Free tool
FAERS Monitor: Columvi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761309 or its brand name (Columvi, Glofitamab-Gxbm). Reports on generic versions are filed under their own applications.
Reports
2,709
Serious
2,487
92% of reports
Hospitalization
872
Death reported
781
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cytokine release syndrome855
- disease progression486
- off label use325
- death304
- pyrexia221
- neutropenia198
- immune effector cell-associated neurotoxicity syndrome156
- covid-19126
- anaemia115
- infection114
- febrile neutropenia107
- pneumonia102
- drug ineffective96
- thrombocytopenia95
- diffuse large b-cell lymphoma recurrent78
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 6 |
| 2020 | 8 |
| 2021 | 60 |
| 2022 | 161 |
| 2023 | 293 |
| 2024 | 639 |
| 2025 | 690 |
| 2026 | 851 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,450 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytokine release syndromeSignal | 855 | 345.6 | 326.4 | 281,223 |
| diffuse large b-cell lymphoma recurrentSignal | 78 | 284.7 | 227.8 | 21,001 |
| immune effector cell-associated neurotoxicity syndromeSignal | 156 | 210.0 | 179.9 | 31,399 |
| disease progressionSignal | 486 | 32.0 | 29.5 | 14,595 |
| febrile neutropeniaSignal | 107 | 12.5 | 10.4 | 1,127 |
| neutropeniaSignal | 198 | 11.3 | 9.9 | 1,862 |
| thrombocytopeniaSignal | 95 | 6.6 | 5.4 | 448 |
| infectionSignal | 114 | 6.1 | 5.1 | 486 |
| covid-19Signal | 126 | 5.6 | 4.7 | 473 |
| pyrexiaSignal | 221 | 5.0 | 4.4 | 706 |
| anaemiaSignal | 115 | 4.7 | 3.9 | 332 |
| off label useSignal | 325 | 2.9 | 2.6 | 415 |
| deathSignal | 304 | 2.7 | 2.5 | 348 |
| pneumoniaSignal | 102 | 2.4 | 2.0 | 87 |
| drug ineffective | 96 | 0.6 | 0.5 | 34 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.